The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Access to Data and Biospecimens, 2020Association of Repetitive DNA Elements in Parkinson’s Disease Risk and Progression
Study Rationale:
Repetitive DNA elements such as “jumping genes” were previously considered ‘junk DNA’. However, it is now known that these elements are involved in the development of several diseases... -
Research Grant, 2019Long-acting GM-CSF Fusion Protein (PDM608) for the Treatment of Parkinson’s Disease
Study Rationale:
Emerging evidence suggests that the modulating the peripheral immune system can be a powerful disease-modifying approach for the treatment of Parkinson's disease (PD). We have... -
Therapeutic Pipeline Program, 2019Oligomeric Alpha-synuclein-specific Antibody-based Gene Therapy
Study Rationale:
Alpha-synuclein is the primary component of Lewy bodies, the hallmark of Parkinson’s disease (PD). In particular, soluble aggregates of alpha-synuclein, also referred to as oligomers... -
Astrocyte Biology in Parkinson's Disease, 2019Astrocyte Gene Expression in Parkinson’s Interrogated Using Single Cell Nuclear RNA Sequencing
Study Rationale:
Astrocytes are one of the major non-neuron cell types in the brain and control many neurological processes. They are likely to be changed in Parkinson’s disease (PD) and may... -
Astrocyte Biology in Parkinson's Disease, 2019Characterization of Astrocytes in Aging and Lewy Body Pathology
Study Rationale:
Astrocytes are brain cells with crucial roles, including communication between nerve cells, clearance of unwanted material, and response to injury. It has been suggested that... -
Therapeutic Pipeline Program, 2019Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability
Study Rationale:
Evidence suggests that levodopa’s efficacy and side effects (uncontrolled movements called dyskinesia) are caused by activating dopamine D1 receptors. An optimal Parkinson’s disease...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.